GLOBAL PRIMARY CELL CULTURE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Global Primary Cell Culture Market, By Product Type (Primary Cells, Instruments, Reagents and Supplements, Media, Other Consumables), By Cell Type (Human Primary Cells, Animal Primary Cells,), By Application (Cell & Gene Therapy Development, Vaccine Production, Drug Discovery and Development, Cancer Research, Prenatal Diagnosis, Others), By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Contract Research Organizations (CROs), Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments

Product Launches

In May 2023, ProBioGen, a Germany-based company that develops and manufactures APIs, launched a novel lentivirus packaging cell line. Lenti.RiGHT is a lentivirus manufacturing platform that utilizes human embryonic kidney 293 packaging cells.
In May 2023, Lonza, a global biotechnology company, announced the launch of TheraPEAK T-VIVO Cell Culture Medium, a novel chemically defined medium designed to improve CAR T-cell production. The medium is free of animal-derived components, which increases consistency and process control while also simplifying regulatory approval for a faster time-to-market.
In January 2022, BioIVT, a provider of research models and services for drug and diagnostic development, announced the launch of its GMP-grade human AB serum, a cell culture supplement to boost the development and manufacture of cell and gene therapies.

Business Development Activities by Market Players

In June 2023, Inventia Life Science, an Australia-based biotechnology company, announced a new distribution agreement with Biotron Healthcare PVT Limited, a diagnostics distributor in the life sciences and biotechnology industries. As a consequence, Biotron Healthcare PVT Ltd has acquired sales rights to Inventia Life Science's flagship RASTRUM platform in the Indian market. The RASTRUM platform assists researchers in their effort to discover and treat debilitating diseases such as cancer, neurological, and fibrotic disorders.
In November 2022, QIAGEN Digital Insights (QDI), QIAGEN's bioinformatics division, announced the launch of a new cell line database built in collaboration with ATCC, a renowned biological materials organization, producer, and supplier of authenticated cells. This database provides carefully selected sequencing data for standardized, authenticated, and repeatable cell lines.
In July 2021, Sartorius, a life science company, announced the acquisition of Xell AG, a cell culture specialist based in Bielefeld, Germany. Xell AG creates, manufactures, and markets media and feed additives for cell cultures, primarily for the production of viral vectors used in gene therapies and vaccinations. Beyond these media, the company provides a variety of analytical services for defining, screening, and measuring media components, as well as improving media composition.